11 results about "MMP3" patented technology

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

The invention discloses a multivalent triangular DNA origami delivery system as well as a preparation method and application thereof, which can be used as a novel method for treating osteoarthritis, and is particularly suitable for patients with cartilage degeneration and joint inflammation caused by age, obesity, joint reuse, sport injury or genetic factors and the like. Specific siRNAs (small interfering RNAs) are delivered by the use of multivalent triangular DNA origami. According to the scheme, the expression of inflammation and degeneration related genes, such as Stat3, MMP3 and MMP13, in cartilage cells in joints can be specifically inhibited, so that the inflammatory response is relieved, cartilage decomposition is inhibited, and repair and regeneration of cartilage tissues are promoted. The invention provides a method for treating osteoarthritis, which has the advantages of strong targeting property, small side effect and obvious curative effect, is suitable for clinical treatment and basic medical research, and has wide application prospect.

The invention belongs to the technical field of microorganisms, and finds that trans-cinnamic acid is a key metabolite of microorganism staphylococcus epidermidis H62-3 for the first time, so that a new method is provided for preparation of the trans-cinnamic acid, and meanwhile, the problem of environmental pollution caused by chemical synthesis of the trans-cinnamic acid is also avoided. In addition, the invention also relates to an application of trans-cinnamic acid in preparation of a product for resisting skin photoaging. The trans-cinnamic acid provided by the invention has the effect of resisting skin photoaging, can effectively relieve the transcriptional level of senescence-related genes p53, p21 and p16 and inflammatory factors IL-1beta, IL-6 and TNF-alpha induced by UVB irradiation, reduces the level of reactive oxygen species (ROS), inhibits the expression of matrix metalloproteinases MMP9, MMP3 and MMP1, promotes the synthesis of I-type collagen (COL1), and can be used for preparing anti-aging drugs for treating skin aging. And the activity of beta-galactosidase (SA-beta-gal) related to aging is reduced.

The present invention relates to a composition which is for preventing or treating bone diseases and includes CCR2 as an active ingredient. It was confirmed that a C—C chemokine receptor type 2 (CCR2) protein, a polynucleotide encoding the CCR2 protein, or a mesenchymal stem cell transduced with the CCR2 according to the present invention neutralize bone disease factor MCP-1, thereby reducing the collagen epitope (CTX-II) and collagen metabolism factors (MMP1 and MMP3) relating to collagen absorption in the body. In addition, it was confirmed that the expression of the SOX9 gene and anti-inflammatory cytokines (TGF-β and IL-10) related to cartilage differentiation was significantly increased. Thus, the present invention has excellent regenerative ability against osteoarthritis and excellent pain suppression and alleviation effects, and thus can be effectively used for preventing or treating bone diseases such as osteoarthritis.

This invention discloses biomarkers for the diagnosis and treatment of gastric cancer. This application proposes a novel non-invasive method for the early detection of peritoneal metastases in gastric cancer patients. The RSA model combines 4-mRNA genomes (BUB1, SPC25, CT83, and MMP3) with clinical characteristics. Furthermore, it provides the application of 4-mRNAs in the treatment of gastric cancer, offering new directions for improving risk stratification, treatment planning, and monitoring of gastric cancer patients, as well as for effective treatment of gastric cancer, and has broad application prospects.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

This invention discloses a circular RNA, circTP63-N, and its applications. This invention discovers a novel circular RNA, circTP63-N, expressed at low levels in nasopharyngeal carcinoma. By directly binding to the HSP90AB1 protein, it promotes the binding of LATS1 / 2 and YAP1 proteins, causing YAP1 phosphorylation and ubiquitination degradation, leading to reduced YAP1 nuclear translocation. This further inhibits the expression of downstream extracellular matrix-related genes INHBA and MMP3, as well as the cell cycle-related gene CCNE2, ultimately suppressing the proliferation, invasion, and migration of nasopharyngeal carcinoma. The discovery of this circular RNA provides a new approach for the diagnosis and treatment of nasopharyngeal carcinoma and has broad application prospects.

The application discloses application of isoprenyl cysteine carboxymethyltransferase as a rheumatoid arthritis treatment target in preparation of a rheumatoid arthritis treatment drug. The application finds that the expression of ICMT is down-regulated after NSUN2 is knocked out, further research on the expression level of ICMT in RA FLS finds that the mRNA and protein expression of RA FLS ICMT is obviously up-regulated, the cell migration and invasion ability is reduced after ICMT is knocked down, and the expression of MMPs such as MMP1, MMP3 and MMP9 of RA FLS is obviously inhibited. The above results show that ICMT can regulate the abnormal migration and invasion of RA FLS, and targeting ICMT can become a new means to prevent RA joint destruction. Therefore, the application provides an effective treatment target for RA, and provides a new idea for clinical treatment of RA.

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.

The invention discloses an application of D-mannose in preparation of a medicine for treating plantar fasciitis and related pains, the active ingredient in the medicine is D-mannose, and the D-mannose inhibits the expression of matrix metalloproteinase-3 (MMP3) caused by inflammation stimulation in plantar fasciitis tissues through a metabolite mannose-6-phosphoric acid (M6P). The invention discloses and verifies that the natural product D-mannose realizes an inhibition effect on a key pathogenic factor MMP3 of plantar fasciitis through a specific metabolic pathway of 'Man-M6P' for the first time, and not only is the drug effect obvious, but also the safety is far better than that of the existing common drugs. Besides, the traditional Chinese medicine composition not simply relieves pain and resists inflammation, but targets an upstream key link MMP3 causing degeneration of fascia tissues, and by inhibiting the MMP3, damage to fascia collagen structures is reduced fundamentally, and conditions are created for self-repairing and regeneration of tissues, so that radical treatment and recurrence prevention are expected to be realized.

The present invention relates to a composition for the prevention or treatment of rheumatoid arthritis, comprising, as an active ingredient, a supercritical extract of Acanthopanax sessiliflorus Harms. In the present invention, it was confirmed that, upon administration of the supercritical extract of Acanthopanax sessiliflorus Harms to a rheumatoid arthritis animal model, pain induced by rheumatoid arthritis was reduced and cartilage damage was suppressed. Also, a decrease in the infiltration of immune cells in cartilage tissue was confirmed, and it was confirmed that the expression of Col2a1, Sox9, and Aggrecan, which are cartilage anabolic factors whose expression is reduced by inflammatory cytokines and inflammatory factors, was increased, and the expression of Mmp3, Mmp10, Mmp13, and Adamts5, which are cartilage catabolic factors, was reduced. It was also confirmed that pimaric acid and kaurenoic acid, which are useful components of the supercritical extract of Acanthopanax sessiliflorus Harms, protected chondrocytes and suppressed the differentiation of Th17 cells, which are pathogenic cells in rheumatoid arthritis.